Cell line name | Caco-2 | ||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms | CaCo-2; CACO-2; Caco 2; CACO 2; CACO2; CaCo2; CaCO2; Caco2; Caco-2/ATCC; Caco-II | ||||||||||||||||||||||||||||||||||||||||||||||
Accession | BTCC-1033 | ||||||||||||||||||||||||||||||||||||||||||||||
Resource Identification Initiative | To cite this cell line use: Caco-2 (BTCC-1033) | ||||||||||||||||||||||||||||||||||||||||||||||
Comments | Part of: AstraZeneca Colorectal cell line (AZCL) panel. Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). Part of: ENCODE project common cell types; tier 3. Part of: MD Anderson Cell Lines Project. Population: Caucasian. Virology: Highly susceptible to infection by SARS coronavirus (SARS-CoV) (PubMed=15316659). Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257; PubMed=34339474). Doubling time: 51.41 hours (PubMed=25944804); 3-4 days (ATCC=HTB-37); ~60-70 hours (CLS=300137); ~80 hours (DSMZ=ACC-169); ~32 hours (PBCF). Microsatellite instability: Stable (MSS) (PubMed=24042735; PubMed=24755471; PubMed=25926053; PubMed=28683746). Omics: CTCF ChIP-seq epigenome analysis. Omics: H3K4me3 ChIP-seq epigenome analysis. Omics: H3K27me3 ChIP-seq epigenome analysis. Omics: H3K36me3 ChIP-seq epigenome analysis. Omics: Deep antibody staining analysis. Omics: Deep exome analysis. Omics: Deep phosphoproteome analysis. Omics: Deep proteome analysis. Omics: miRNA expression profiling. Omics: N-glycan profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: SNP array analysis. Omics: Transcriptome analysis by microarray. Omics: Transcriptome analysis by RNAseq. Omics: Transcriptome analysis by serial analysis of gene expression (SAGE). Derived from site: In situ; Colon; UBERON=UBERON_0001155. | ||||||||||||||||||||||||||||||||||||||||||||||
Sequence variations |
| ||||||||||||||||||||||||||||||||||||||||||||||
HLA typing | Source: PubMed=25960936
Source: PubMed=26589293
Source: CLS=300137
| ||||||||||||||||||||||||||||||||||||||||||||||
Genome ancestry | Source: PubMed=30894373
| ||||||||||||||||||||||||||||||||||||||||||||||
Disease | Colon adenocarcinoma (NCIt: C4349) | ||||||||||||||||||||||||||||||||||||||||||||||
Species of origin | Homo sapiens (Human) (NCBI Taxonomy: 9606) | ||||||||||||||||||||||||||||||||||||||||||||||
Hierarchy | Children:
| ||||||||||||||||||||||||||||||||||||||||||||||
Sex of cell | Male | ||||||||||||||||||||||||||||||||||||||||||||||
Age at sampling | 72Y | ||||||||||||||||||||||||||||||||||||||||||||||
Category | Cancer cell line | ||||||||||||||||||||||||||||||||||||||||||||||
STR profile | Source(s): AddexBio; ATCC; CCRID; CLS; DSMZ; ECACC; PubMed=11416159; PubMed=25877200; PubMed=25926053; RCB Markers:
Run an STR similarity search on this cell line | ||||||||||||||||||||||||||||||||||||||||||||||
Web pages | https://en.wikipedia.org/wiki/Caco-2 https://www.atcc.org/en/support/technical-support/faqs/growth-rate-of-atcc-htb-37 https://www.atcc.org/en/support/technical-support/faqs/morphology-of-atcc-htb-37 https://www.phe-culturecollections.org.uk/media/171256/caco-2-cell-line-profile.pdf https://www.proteinatlas.org/learn/cellines http://www.sygnis.com/caco-2/ https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/c/cell-lines-detail-37.html http://www.cyprotex.com/admepk/in-vitro-permeability/caco-2-permeability/ https://www.synapse.org/#!Synapse:syn31544480 https://tcpaportal.org/mclp/ | ||||||||||||||||||||||||||||||||||||||||||||||
Publications | PubMed=327080; DOI=10.1093/jnci/59.1.221 PubMed=833871; DOI=10.1093/jnci/58.2.209 PubMed=6935474; DOI=10.1093/jnci/66.2.239 PubMed=7459858 PubMed=3518877; DOI=10.3109/07357908609038260 PubMed=3349466 PubMed=2914637; DOI=10.1016/0016-5085(89)90897-4 PubMed=7764660; DOI=10.1007/BF00749813 PubMed=8508948; DOI=10.1111/j.1432-0436.1993.tb00645.x PubMed=9294210; DOI=10.1073/pnas.94.19.10330 PubMed=10612807; DOI=10.1002/(SICI)1098-2264(200002)27:2<183::aid-gcc10>3.0.CO;2-P PubMed=10737795; DOI=10.1073/pnas.97.7.3352 PubMed=11414198; DOI=10.1007/s004320000207 PubMed=11668190; DOI=10.1177/002215540104901105 PubMed=12584437; DOI=10.1159/000068544 PubMed=14599474; DOI=10.1016/S0887-2333(03)00095-X PubMed=15316659; DOI=10.1007/s00018-004-4222-9 |
Cell line collections (Providers) | Abcam; ab275464 - Discontinued AddexBio; C0009009/29 ATCC; HTB-37 BCRJ; 0059 CCTCC; GDC0153 CLS; 300137 DSMZ; ACC-169 ECACC; 09042001 ECACC; 86010202 IBRC; C10094 ICLC; HTL97023 IZSLER; BS TCL 87 KCB; KCB 200710YJ KCLB; 30037.1 NCBI_Iran; C139 RCB; RCB0988 |
---|---|
Chemistry resources | ChEMBL-Cells; CHEMBL3307519 ChEMBL-Targets; CHEMBL614058 PharmacoDB; Caco2_161_2019 PubChem_Cell_line; CVCL_0025 |
Encyclopedic resources | Wikidata; Q5016050 |
Experimental variables resources | EFO; EFO_0001099 |